Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- CheckyesterdayChange DetectedA banner announces changes to NIH website terminology, including the use of “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check8 days agoChange DetectedThe site’s footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record, with the 403 header and a site footer visible, indicating the trial details are inaccessible at this time.SummaryDifference19%

- Check56 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6. This reflects a version bump for the page rather than a substantive change to study details.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, representing a small backend/content management update.SummaryDifference0.1%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.